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10Efﬁcacy of thoracic endovascular stent repair for
chronic type B aortic dissection with aneurysmal
degeneration
Salvatore T. Scali, MD,a Robert J. Feezor, MD,a Catherine K. Chang, MD,a David H. Stone, MD,c
Philip J. Hess, MD,b Tomas D. Martin, MD,b Thomas S. Huber, MD, PhD,a and Adam W. Beck, MD,a
Gainesville, Fla; and Lebanon, NH
Background: The Food and Drug Administration has approved devices for endovascular management of thoracic endo-
vascular aortic aneurysm repair (TEVAR); however, limited data exist describing the outcomes of TEVAR for aneurysms
attributable to chronic type B aortic dissection (cTBAD). This study was undertaken to determine the results of endo-
vascular treatment of cTBAD with aneurysmal degeneration.
Methods: A retrospective analysis of all patients treated for cTBAD with aneurysmal degeneration at the University of
Florida from 2004 to 2011 was performed. Computed tomograms with centerline reconstruction were analyzed to
determine change in aortic diameter, relative proportions of aortic treatment lengths, and false lumen perfusion status.
Reintervention and mortality were estimated using life-tables. Cox regression analysis was completed to predict mortality.
Results: Eighty patients underwent TEVAR for aneurysm due to cTBAD (mean age [6 standard deviation], 60 6 13 years
[male, 87.5%; n[ 70];median follow-up, 26 [range, 1-74]months).Median time fromdiagnosis of TBAD toTEVARwas 16
(range, 1-72) months. Prior aortic root/arch replacement had been performed in 29% (n [ 23) at a median interval of
28.5 (range, 0.5-312) months. Mean preoperative aneurysm diameter was 62.06 9.9 mm. In 75% (n[ 60) of cases, coverage
was proximal to zone 3, and 24% (n[ 19) underwent carotid-subclavian bypass or other arch debranching procedure. Spinal
drainswere used in 78% (pre-op71%, n[57; post-op6%, n[5). Lengthof staywas 6.564.7dayswith a compositemorbidity
of 26%and in-hospitalmortality of 2.5% (n[2).Overall neurologic event ratewas 17% (spinal cord ischemia10% [n[8],with
a permanent deﬁcit observed in 6.2% [n[ 5]; stroke 7.5%). Aneurysm diameter reduced or stabilized in 65%. The false lumen
thrombosed completely within the thoracic aorta in 52%, and reintervention within the treated aortic segment was required in
16% (n[13).One- and3-year freedomfromreintervention (with 95% conﬁdence interval [CI])was 80% (range, 68%-88%) and
70% (range, 57%-80%), respectively. Survival at 1 and5 yearswas 89% (range, 80%-94%) and70% (range, 55%-81%) andwas not
signiﬁcantly different among patients requiring reintervention or experiencing favorable aortic remodeling. Multivariable
analysis identiﬁed coronary artery disease (hazard ratio [HR], 6.4; 95% CI, 2.3-17.7; P < .005), prior infrarenal aortic surgery
(HR, 8.6; 95% CI, 2.3-31.7; P[ .001), and congestive heart failure (HR, 11.9; 95% CI, 1.9-73.8; P[ .008) as independent
risk factors for mortality. Hyperlipidemia was found to be protective (HR, 0.2; 95% CI, 0.05-0.6; P[ .004). No signiﬁcant
difference in predictors ofmortality were found between patients who underwent reintervention vs those who did not (P[ .2).
Conclusions: TEVAR for cTBAD with aneurysmal degeneration can be performed safely but spinal cord ischemia rates
may be higher than previously reported. Liberal use of procedural adjuncts to reduce this complication, such as spinal
drainage, is recommended. Reintervention is common, but long-term survival does not appear to be impacted by
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is increasingly performed to treat a variety of acute and
chronic aortic pathologies1,2; however, its role in the
management of dissection-related diseases remains contro-
versial. Although there are large clinical trials and registries
examining outcomes of patients with acute aortic dissec-
tion,3,4 results of chronic dissection treated with TEVAR
are primarily retrospective, single center experiences
comprised of heterogeneous cohorts of acute, subacute,
and chronic presentations with varying operative indications
(eg, pain, malperfusion, false lumen [FL] aneurysm).
Patients who develop chronic thoracic or thoracoabdominal
FL aneurysmal dilatation have traditionally been treated
with open surgery, but substantial morbidity and mortality
have been described with these repairs.5,6 Given the success
of TEVAR in the management of degenerative aneurysms,
this therapy offers an attractive alternative to open surgery
for chronic dissection with aneurysmal dilatation.7,8 How-
ever, the presence of a mature, rigid dissection ﬂap and
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endovascular therapy, and the long-term durability of endo-
vascular management remains in question.9
The primary objective of managing aneurysms result-
ing from chronic type B aortic dissection (cTBAD) is to
prevent patient death from rupture. This clinical end
point is frequently associated with the ability of TEVAR
to trigger favorable aortic remodeling and, consequently,
it is thought that an important predictor of outcome is
the status of FL patency.10 Because of the need for reinter-
vention in 18%-50% of patients, a consensus deﬁnition of
‘clinical success’ remains elusive, particularly in patients
with dissection extending into the visceral segment.7,11
Although short-term outcomes of TEVAR for cTBAD
have been reported to have high technical success rates
and acceptable morbidity, concerns over precipitation of
retrograde dissection or visceral ischemia remain.12,13
Because of these concerns over efﬁcacy, safety, and dura-
bility, Food and Drug Administration approval of chronic
dissection as an indication for TEVAR has not yet
occurred.
The purpose of this analysis is to provide midterm
results of patients treated electively for cTBAD complicated
by aneurysmal dilatation. Speciﬁcally, results of periopera-
tive outcomes, secondary intervention, mortality, and
impact of aortic remodeling will be described.
METHODS
Database and study cohort. A prospectively main-
tained endovascular aortic registry at the University of Flor-
ida was queried for all patients undergoing TEVAR from
January 2004 to December 2011. Patients treated for
degenerative and trauma-related pathology (including
aneurysm, penetrating ulcer, atheromatous disease, pseu-
doaneurysm, and traumatic transection) were excluded.
Patients with dissection-related indications were further
reviewed, and only elective procedures performed for
aneurysmal degeneration of descending aortic dissection
were included. Patients with thoracoabdominal FL aneu-
rysm managed with chimney, fenestration, or visceral
debranching procedures were omitted. However, patients
who received a distal aortic stent (graft) and/or renal/
visceral stent graft to treat a large secondary entry tear in an
attempt to further reduce FL perfusion of the thoracic
aneurysm were included. Patients with a primary entry tear
located distal to the left subclavian artery and concomitant
descending thoracic FL aneurysm comprised the study
cohort (Supplementary Fig, online only). While acute
proximal dissections (Stanford A14 or Debakey I/II15) were
not included, patients treated for type A dissection with
residual cTBAD with aneurysm formation were analyzed.
Additionally, patients requiring bypass or stenting for
revascularization of great vessels to augment the proximal
landing zone for descending dissection cases were
included. Indication for TEVAR was maximal thoracic
aneurysm diameter $6.0 cm or documented growth rate
$1.0 cm on serial centerline computed tomography (CTA)
measurements over 12 months.The electronic medical record was reviewed to collect
demographics, comorbidities, procedure speciﬁc details,
reinterventions, and complications. Comorbidities were
deﬁned based on previously published deﬁnitions from
the Society of Vascular Surgery.16,17 Reintervention was
deﬁned as any aortic-related endovascular or open surgical
procedure that occurred after the index TEVAR either at
the intended treatment zone or at remote aortic sites.
Patient mortality was conﬁrmed utilizing the Social Secu-
rity Death Masterﬁle.
Clinical practice. All operations were performed elec-
tively in a hybrid operating room using regional or general
anesthesia. Need for preoperative or intraoperative adjuncts
(eg, carotid-subclavian bypass, open/endovascular access
vessel conduit) were determined selectively by each
surgeon. Preoperative spinal drainage was used selectively
according to previously published guidelines from our
group.18,19 Intravascular ultrasound was used in all cases to
conﬁrm traversal of the wire through the true lumen,
evaluate septal mobility pre- and post-stent deployment,
assist endograft positioning, and evaluate expansion of the
endograft after deployment. All patients undergoing repair
were administered systemic heparin (100 U/Kg) to achieve
an activated clotting time of $300 seconds. Devices were
oversized 10%-15% relative to the diameter of the normal
aorta proximal to the dissection, with little consideration
given to sizing of the distal graft given the often very small
true lumen diameter. Compliant balloon angioplasty of the
proximal or distal stent was not routinely performed but
selectively employed in the event of type I endoleak.
Technical success was deﬁned as deployment of the
endograft at the intended aortic segment with absence of
antegrade ﬂow into the FL/aneurysm at case completion.
Coverage length was chosen with the goal of excluding
the entire dissected aorta and all fenestrations in the cases
of Debakey IIIa dissection.15 For Debakey IIIb dissec-
tions,15 there was some variability in treatment length
based on surgeon’s discretion. Early in our experience,
coverage length was often determined intraoperatively
based on the goal of covering the primary fenestration, as
well as any obvious large fenestrations noted on intravas-
cular ultrasound, and the ability to incite sluggish or no
evident FL ﬂow on aortography after endograft deploy-
ment. Because of the frequent need for reintervention,
our current practice has evolved to more aggressive aortic
coverage, and we now generally treat down to the celiac
artery in all patients.
Postoperative care occurred in a cardiovascular inten-
sive care unit, and management of the spinal drain was
based on a previously published protocol.18,19 Spinal cord
ischemia (SCI) was deﬁned as any new impairment in
lower extremity motor and/or sensory deﬁcit not attribut-
able to intracranial pathology, peripheral neuropathy, or
neuropraxia. The diagnosis was determined by the treating
physician and conﬁrmatory imaging (eg, magnetic reso-
nance imaging [MRI]), and clinical consultation with
a neurologist were employed in selected cases when the
diagnosis was not clear.
Table I. Patient demographics, comorbidities, dissection
morphology, and previous aortic surgery history
Feature % (n ¼ 80)
Age (mean 6 SD), years 60 6 13
Male 88
Hypertension 95
Dyslipidemia 53
Tobacco 51
CRI (eGFR <50) 30
Coronary artery disease 19
COPD 16
Arrhythmia 11
Marfan’s 9
Peripheral artery disease 9
Cerebrovascular disease 8
Dissection extenta
Debakey IIIa 24
Debakey IIIb 76
Previous aortic operation
Infrarenal AAA repair 10
Type A repairb 9
Asc. and arch repair 9
Elephant trunk 5
AAA, Abdominal aortic aneurysm; Asc., ascending aortic arch; COPD,
chronic obstructive pulmonary disease; CRI, chronic renal insufﬁciency;
eGFR, estimated glomerular ﬁltration rate; SD, standard deviation.
aDebakey extents IIIa/b.14
bStanford type A,15proximal aortic dissection.
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including persistent FL ﬂow into the treated segment
with further aneurysmal enlargement, type I or III endo-
leak, erosion of the graft through the dissection septum
with pain or recurrent FL ﬂow, device failure (eg, infold-
ing), and aneurysmal degeneration of the untreated prox-
imal or distal aorta.
Imaging protocol, aortic measurements, and deﬁ-
nitions. Preoperative imaging for all patients included
CTA with 1-2 mm cuts, including arterial and venous
phase images, which was further analyzed on an Aquarius
workstation (TeraRecon, Inc, San Mateo, Calif). Postoper-
ative surveillance was based on a similar protocol with
imaging at 1 month, 6 months, and annually thereafter.
Postoperative centerline of ﬂow reconstructions were
completed from the sinotubular junction (STJ) to the
aortic bifurcation. Measurements lengths included
STJ/aortic bifurcation (total aortic length: [TAL]), left
carotid artery (LCCA)/celiac artery (thoracic aortic
length [ThAL]), and total coverage length of the thoracic
endograft(s) (TCL). Percentage of total aortic coverage
(TAC) and thoracic aortic coverage (ThAC) were cal-
culated as follows: %TAC ¼ (TCL/TAL)  100;
%ThAC ¼ (TCL/ThAL)  100.
FL patency was deﬁned by contrast within the FL on
arterial or venous phase of CTA. FL thrombosis was charac-
terized by the following zone designations: complete (no
contrast blush in any segment of the aorta), proximal
thoracic (site of the TEVAR treatment zone or proximal
to T6), distal thoracic (below T6, but above the celiac
artery), visceral segment ( between celiac axis and lowest
renal artery), infrarenal aortic (lowest renal artery to aortic
bifurcation), and iliac ( aortic bifurcation to iliac bifurcation).
Using this classiﬁcation, further analysis of the status of
residual FL patency was completed by categorizing patients
into the following subgroups: entire FL thrombosed except
(1) isolated segment of infrarenal aorta FL, (2) visceral
segment FL patent but complete thrombosis of thoracic
segment, or (3) distal thoracic aortic FL patent but throm-
bosis of the proximal, treated segment of the thoracic aorta.
Finally, trans-aortic diameters were measured on preopera-
tive and most recent postoperative CTA at multiple sites
within the thoracic aorta. Favorable aortic remodeling was
deﬁned by a $5 mm thoracic aneurysm diameter reduction
and no need for aortic-related reintervention.
Statistical analysis. Categorical variables were summa-
rized using frequencies and percentages. Continuous vari-
ables were analyzed with means and standard deviations if
normally distributed; otherwise medians with range were
applied. Comparisons of patient- or procedure-related
characteristics in subgroup analysis were performed using
Fischer exact test, two-sample t-test, Wilcoxon rank sum
text, and ANOVA, when appropriate. Patient survival and
reintervention rates were estimated using Kaplan-Meier
methodology and compared between groups using the
log-rank test. Cox regression analysis was utilized to develop
a model to predict mortality. Variables found on univariate
analysis to have P < .2 were included in the multivariablemodel, which was reﬁned using stepwise backward Cox
regression and log-likelihood ratio testing. All statistical
analysis was performed using STATA 11 software (Stata-
Corp, College Station, Tex).
RESULTS
From 2004 to 2011, 635 patients were treated with
TEVAR for a variety of aortic pathologies, of whom 80
underwent repair for asymptomatic FL aneurysms attribut-
able to cTBAD. Speciﬁcally, the indication for intervention
was thoracic aneurysm $6.0 cm (n ¼ 51; 63.8%) or aneu-
rysm expansion $1.0 cm during a 12-month interval (n ¼
29; 36.2%). Median time from diagnosis of acute dissection
to TEVAR for chronic aneurysm was 16 (range, 1-74)
months. Most patients were male (n ¼ 70; 88%; mean
age 60 6 13 years), and median follow-up was 24 (range,
1-72) months. Demographics and preoperative characteris-
tics are further highlighted in Table I.
Procedural details and perioperative outcomes.
Technical success was achieved in 79 cases (99%), with one
intraoperative type Ia endoleak. Two patients (2.5%) had
type 1a endoleak on their 1-month postoperative CTA.
In 75% (n ¼ 60) of patients, coverage occurred proximal to
zone 3, and 30% (n ¼ 18) of these patients underwent
subclavian revascularization. Additional data regarding
technical conduct of the TEVAR procedure are detailed in
Table II. All patients were treated with covered stent grafts,
and no self or balloon expandable bare metal stents were
employed to augment radial force in an effort to improve
true lumen expansion. Mean proportion of total aortic and
Table II. Operative details
Feature % (n ¼ 80)
Preoperative aneurysm diameter (mean 6 SD), mm 62 6 10
Stent graft type
Gore TAG 50
Cook TX2 50
Procedure details
Spinal anesthesia 51
ASA score (III/IV) 99
Cerebrospinal ﬂuid drain
Preoperative 71
Postoperative 6
Left subclavian coverage 75
Carotid subclavian bypass 20
Intraoperative adjunct (any) 39
Visceral/renal stent graft 20
Simultaneous aortic stent graft 16
Iliac artery stent graft (to treat distal fenestration) 15
Left subclavian embolization 6
Access vessel conduit 4
Arch vessel stent graft 3
Palmaz stent 3
ASA, American Society of Anesthesiologists; SD, standard deviation.
Table III. Clinical outcomes and complications
Feature % (n ¼ 80)
LOS (mean 6 SD), days 6.5 6 4.7
30-day mortality 2.5
Complication 26
Spinal cord ischemia
Any SCI 10
Permanent 6
Stroke 8
Pulmonary 4
Cardiac 3
Bleeding (access vessel) 3
Renal (25 Y eGFR) 1
Gastrointestinal 1
eGFR, Estimated glomerular ﬁltration rate; LOS, length of stay; SCI, spinal
cord ischemia; SD, standard deviation.
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78.2 6 19.3%, respectively.
Spinal drains were used in 78% (n ¼ 62) of the proce-
dures with 57/62 (92%) placed preoperatively, and 8%
(n ¼ 5) implanted postoperatively. Length of stay was
6.5 6 4.7 days, and 21(26%) patients experienced some
complication. Further details regarding outcomes and
complications are demonstrated in Table III. Notably,
a total of 14(17%) patients experienced some form of neuro-
logic morbidity. A permanent deﬁcit (either from SCI or
stroke) was documented in 11.2% of patients. More specif-
ically, SCI developed in 10% (n ¼ 8), with a permanent
deﬁcit observed in 6.2% (n ¼ 5). The remaining neurologic
events (n ¼ 6; 7.5%) were MRI-evident cerebrovascular
infarctions, and four (5%) cases resulted in permanent
disability. For the entire cohort, there were two in-
hospital deaths (2.5%). One of the patients experienced
a devastating posterior stroke and subsequently died on
postoperative day 15. The second patient suffered multiple
complications including SCI and respiratory failure, and
support was withdrawn on postoperative day 11.
A decreased incidence of SCI was noted in patients
who underwent preoperative spinal drain placement
(5.3%; n ¼ 57) compared with those who did not
(21.7%; n ¼ 23; P ¼ .04). No signiﬁcant association was
found between SCI and planned left carotid-subclavian
bypass (P ¼ .3), although there was a trend toward a lower
incidence with carotid-subclavian bypass (0% in 16 patients
compared with 12.5% in 64). Finally, there was no differ-
ence in ThAC between patients who developed SCI and
those who did not (83% vs 78%; P ¼.6).
Aortic remodeling and secondary intervention.
Clinical and radiographic follow-up was available in 74
(93%) patients with median clinical and radiographic
follow-up times of 25.8 (range, 7-38) and 18.1 (range,1-34) months, respectively. Postoperative CTA beyond 12
months was available in 63 (79%) patients (noncontrast
CT, n ¼ 13; no postoperative CT available ¼ 4). Aneurysm
diameter decreased or stabilized in 65% (n ¼ 52) whereas
the FL thrombosed completely within the thoracic aorta in
51% (n ¼ 41). For the entire cohort, mean decrease in
diameter of the treated thoracic aortic segment was 2.6 6
10.1 mm. The impact of FL thrombosis on changes in
aortic diameter is depicted in Fig 1. A signiﬁcant difference
(P ¼ .02) in the mean diameter decrease is noted between
patients experiencing complete vs partial FL thrombosis.
Further analysis of the association of FL thrombosis to
aortic remodeling is highlighted in Fig 2. The majority of
patients did not have complete FL thrombosis (50/63; 79%)
because of involvement of the visceral aorta. Those without
complete FL thrombosis had varying segments of residual
FL patency. When comparing mean thoracic aortic diameter
change afterTEVAR, a signiﬁcant difference (P< .0005)was
noted between groups with persistent FL perfusion isolated
to the distal thoracic aorta (increase 5.56 1.4mm), involving
the visceral aorta (decrease 2.26 1.7mm), or localized to the
infrarenal aorta (decrease 6.36 3.4 mm).
Twenty-three (29%) patients required some form of
reintervention, with reintervention within the original
treated aortic segment occurring in 16% (n ¼ 13). Median
time to reintervention was 17 (range, 4-33) months with
1- and 3-year freedom from reintervention (95% conﬁ-
dence interval [CI]) of 80% (range, 68%-88%) and 70%
(range, 57%-80%), respectively (Fig 3). There were six
open conversions requiring TEVAR explantation (one sus-
pected aortoesophageal ﬁstula and ﬁve patients with persis-
tent FL expansion from proximal or distal endoleak), and
a variety of remedial procedures were employed to treat
residual degeneration of the FL at remote aortic sites
(Table IV). Six patients underwent more than one
secondary intervention (two reinterventions, n ¼ 3; three
reinterventions, n ¼ 3). Of note, no delayed FL ruptures
or distal endograft collapse occurred in any patient, and
none of the reinterventions resulted in perioperative
mortality. No signiﬁcant association was found between
time from diagnosis of dissection to index TEVAR and
Fig 1. This ﬁgure demonstrates the relative change in maximal
descending thoracic aortic diameter after thoracic endovascular aortic
aneurysm repair (TEVAR) for chronic type B aortic dissection
(cTBAD)withaneurysm.Thedifferential impactofpartial vs complete
thrombosis of the false lumen (FL) led to signiﬁcant differences (P ¼
.02) in average diameter reduction after endograft repair.
Fig 2. This demonstrates a comparison of the average maximal
thoracic aortic diameter change after thoracic endovascular aortic
aneurysm repair (TEVAR) for chronic type B aortic dissection
(cTBAD) with aneurysm formation as a function of residual false
lumen (FL) patency. Patients with isolated infrarenal FL patency vs
visceral aortic segmental patency vs distal descending thoracic
aortic FL patency are compared. A signiﬁcant difference (P <
.0005) in diameter outcome is noted and primarily impacted by
persistent perfusion of the FL in the distal descending thoracic
aorta resulting in progression of aneurysm size.
Fig 3. Kaplan-Meier curve with 95% conﬁdence intervals (CIs) of
secondary intervention after thoracic endovascular aortic aneurysm
repair (TEVAR) for chronic type B aortic dissection (cTBAD) with
aneurysm. All displayed intervals have #10% standard error of the
mean.
Table IV. Secondary interventions after TEVAR for
cTBAD with aneurysm
Feature % (n ¼ 80)
Time to reintervention (median), months 17
Patients 29
Open surgery
Descending thoracic aorta 8
Ascending/arch 4
Carotid subclavian bypass 1
Endovascular
Extension (proximal/distal) 6
Embolization 6
Visceral, renal, and/or iliac stent graft 4
cTBAD, Chronic type B aortic dissection; TEVAR, thoracic endovascular
aortic aneurysm repair.
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remodeling (P ¼ .4). Furthermore, incidence of favorable
aortic remodeling was similar across all quartiles of time
from dissection diagnosis to TEVAR (P ¼ .4).
Mortality. Estimated actuarial 1- and 5-year survival
was 89% (range, 80%-94%) and 70% (range, 55%-81%),
respectively (Fig 4). To study the impact of reintervention
and aortic remodeling on mortality, patients were further
analyzed based on need of secondary aortic-related
procedures, as well as presence or absence of positive aortic
remodeling. Reintervention and favorable aortic remodel-
ing did not have a signiﬁcant inﬂuence on survival (Figs 5
and 6). However, survival analysis suggested a trend
toward improved survival in patients with reintervention.In an attempt to understand differences in the patient
populations of those requiring reintervention and those
who did not, a multivariable prediction model for long-
term mortality was created. This model identiﬁed coronary
artery disease (hazard ratio [HR], 6.4; 95% CI, 2.3-17.7;
P < .005), prior infrarenal aortic surgery (HR, 8.6; 95%
CI, 2.3-31.7; P ¼ .001), and congestive heart failure (HR,
11.9; 95% CI, 1.9-73.8; P ¼ .008) as independent risk
factors associated with increased mortality. Hyperlipidemia
was found to be protective (HR, 0.2; 95% CI, 0.05-0.6;
P¼ .004). No signiﬁcant difference in predictors of survival
were found between patients undergoing reintervention vs
those who did not (P ¼ .2), although a trend was noted
toward increased risk factors in patients not requiring
reintervention.
DISCUSSION
This report is one of the largest series to date that high-
lights the perioperative outcomes, midterm reintervention,
and long-term survival of a cohort of patients treated with
TEVAR for FL aneurysm formation secondary to cTBAD.
Fig 4. Life table estimate of long-term survival with 95% conﬁ-
dence intervals (CIs) after thoracic endovascular aortic aneurysm
repair (TEVAR) for chronic type B aortic dissection (cTBAD) for
aneurysm. All displayed intervals have #10% standard error of the
mean.
Fig 5. This ﬁgure compares the proportion of patients surviving
between cohorts requiring reintervention and those who did not.
No statistically signiﬁcant difference was noted between the two
subgroups (log-rank, P ¼ .48). All displayed intervals have #10%
standard error of the mean.
Fig 6. Kaplan-Meier estimates of survival dichotomized by pres-
ence or absence of favorable aortic remodeling. Favorable aortic
remodeling was deﬁned as a $5 mm decrease in maximal
descending thoracic aortic diameter and no need for aortic rein-
tervention either at the intended treatment zone or remote aortic
sites. No difference in estimated long-term survival is present
between the two groups (log-rank, P ¼ .18). All displayed intervals
have #10% standard error of the mean.
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TEVAR series for degenerative8,20 and dissection-related
pathology; however, rates of spinal cord injury were higher
than previously reported.7,21 A majority of patients had
thrombosis of the intended treatment site within the
thoracic aortic segment with aneurysm stabilization or
reduction. Secondary intervention was common, but reme-
diation or lack of favorable aortic remodeling did not
appear to signiﬁcantly impact long-term survival.
Most centers advocate selective intervention for acute
TBAD, with medical management being the cornerstone
of therapy in uncomplicated cases.22,23 Medical therapy for
uncomplicated chronic descending thoracic aortic dissection
has previously been shown to be equivalent to endovascular
treatment; however, the 2-year event-free survival rate for
the medical arm was only 74%.24 This underscores the
need for long-term radiographic surveillance attributableto FL expansion in 25%-40%, with 10%-20% of patients expe-
riencing late rupture as a result of aneurysm formation.9
Results of open surgical repair for TBAD have variable
outcomes depending on acuity, patient comorbidity proﬁle,
and hospital volume, with a reported in-hospital mortality
rate ranging from 5% to 20%.25,26 In this study, there was
no open cohort for comparison, and given the risk of compli-
cations and reintervention, open therapy may still be an
attractive option for selected patients. Interestingly, Svens-
son and colleagues12 performed a review of contemporary
open surgical series for elective descending thoracic aortic
aneurysm repair, including those attributable to chronic
dissection, and reported an average permanent lower
extremity paralysis rate of 3.4%, stroke rate of 2.7%, and
mortality of 4.8% leading to a recommendation of open
surgical repair in low-risk patients.
The role of TEVAR for cTBAD remains undeﬁned
because of the lack of consensus regarding deﬁnitions of
clinical success and concerns about treatment failure.12,13
A variety of methods have been described to deﬁne aortic
remodeling after TEVAR for cTBAD, including false:true
lumen ratios, volumetry, and diameter changes over
time.4,27,28 Unlike degenerative aneurysms, complete
aneurysm exclusion in dissection patients is often difﬁcult
to achieve because of distal septal tears. Despite this limita-
tion, a similar number of patients undergoing TEVAR for
cTBAD (15%-30%) require adjunctive procedures or need
future reintervention as patients with degenerative aneu-
rysm (12%-22%),7,9,27,29 and the majority of patients
achieve FL thrombosis parallel to the stent graft, similar
to our series.7,11,27 Given the low risk of reintervention
and the apparent lack of adverse impact on mortality, dili-
gent follow-up and judicious reintervention have become
important aspects of our management algorithm.
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cTBAD aneurysms are the potential for endograft collapse
because of a noncompliant dissection ﬂap, visceral vessel
ischemia (if branch vessels receive dual or sole perfusion
from the FL), and intimomedial erosion.30 Despite the
frequent presence of a small distal true lumen diameter
and rigid dissection septum, these complications were rare
in our experience. One patient in this series experienced
late distal endograft collapse that resulted in lower extremity
claudication and postprandial symptoms suggestive of
chronic mesenteric ischemia. This patient was successfully
managedwith TEVAR relining and Palmaz stent placement.
Perhaps the most dreaded complication from these
interventions is precipitation of retrograde dissection,
which has been reported to occur in up to 4% of cases.27,30
In our series, a single retrograde dissection was noted
(1.2%) and occurred 3 months after the index TEVAR.
This patient presented with acute chest pain and was
managed by arch replacement with the Dacron graft
sewn to the endograft in the proximal descending thoracic
aorta. These events underscore the current limitations of
stent graft design for chronic dissection because, in the
majority of cases, treatment extends to the left common
carotid artery, and the endograft frequently must adapt
to signiﬁcant differences in lumen diameter between
the proximal and compressed distal true lumen. The
next generation of stent graft design will likely have
pathology-speciﬁc device modiﬁcations to address these
challenges (eg, Provisional ExTension To Induce COmplete
ATtachment [PETTICOAT31] technique now being evalu-
ated for acute dissection).
Composite perioperative morbidity was 26%, similar to
results from other series; however, the rate of stroke and
SCI was higher than the 0%-4% incidence reported in the
literature.7, 9,12,27,29 This may be a reﬂection of the aggres-
sive posture that is taken in managing FL aneurysms at our
institution whereby the majority of the thoracic aorta
(78.2 6 19.3%) was covered. Of note, the incidence of
SCI was lower in patients who had a preoperative spinal
drain placed. Regarding known risk factors for SCI with
TEVAR, four of the SCI patients had previous infrarenal
aortic surgery, all had patent internal iliac vessels, and seven
of the eight individuals required zone 2 coverage but did
not undergo carotid-subclavian bypass. All of these cases
occurred before 2009 and since that time, 34 TEVAR
procedures for cTBAD have been completed without
SCI. Over this interval, we implemented a protocol with
routine cerebrospinal ﬂuid drainage and subclavian revas-
cularization for all cTBAD with aneurysm cases.
Notwithstanding the signiﬁcant reintervention and
perioperative morbidity, long-term survival in this series
was excellent. The 1- and 5-year survival rates of 80% 6
4% and 70% 6 6% are similar to other series.7,27 These
outcomes occurred despite a relatively high-risk patient
population, with 83% (n ¼ 66) having an American Society
of Anesthesiologists (ASA) score of 4 preoperatively. Inter-
estingly, patients who required reintervention were noted
to have less overall comorbidity than those who did notand may partially explain the trend toward a survival advan-
tage (Fig 5), however, this was not statistically signiﬁcant.
Finally, no signiﬁcant difference in predictors of mortality
were found between patients who underwent reinterven-
tion vs those who did not (P ¼ .2).
This report has several important limitations including
that it is a single center, retrospective analysis without an
open surgical cohort for comparison. Although no signiﬁ-
cant mortality difference was noted when considering rein-
tervention or favorable aortic remodeling, the modest
number of events and duration of the follow-up interval
underscores the potential of type II error. Cause of late
death is not known, and it is conceivable that some of these
events were dissection-related. Although we performed
a multivariable prediction model for survival in an attempt
to understand the impact of reintervention on outcome,
comorbidity severity and medication history (eg, statin
utilization) were not accounted for in the regression anal-
ysis. There was no standardized treatment algorithm in
place over the entire study interval regarding patient selec-
tion and procedural conduct, although since 2009 our
practice has become more uniform.
Because of the lack of consensus on deﬁnition of clin-
ical success or favorable aortic remodeling, the results high-
lighted in this series may not be directly comparable to
other reports of TEVAR for cTBAD. Additionally, postop-
erative CTA was not available for all patients and only two
timepoints were analyzed to discern FL morphology and
aortic diameter. Moreover, no volumetric data were
abstracted, which may offer a more comprehensive and
precise assessment of aortic remodeling for dissection-
related pathology.27 FL patency status was detected from
the arterial and venous phase of postoperative CTA, and
it is conceivable that this is not the most sensitive or speciﬁc
method for analyzing this end point given reports on efﬁ-
cacy of various dynamic MRI techniques.32,33
In conclusion, thoracic endovascular repair of FL aneu-
rysmal degeneration resulting from cTBAD can be per-
formed with a high degree of technical success with
acceptable perioperative morbidity and mortality. Spinal
cord ischemia may occur at a higher incidence than previ-
ously reported, and liberal use of adjuncts such as spinal
drainage and subclavian revascularization is recommended
to reduce the risk of this complication. Lack of uniform
aneurysm diameter reduction, frequent need for reinter-
vention, and variable FL thrombosis underscore the need
for longer-term follow-up. Despite the need for reinterven-
tion and potential procedural morbidity, good long-term
survival can be anticipated.AUTHOR CONTRIBUTIONS
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